Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Rapid Communications in Mass Spectrometry : RCM
|
February 19, 2003
High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays
Jens-Oliver Koopmann, Jonathan Blackburn
Molecular Immunology
|
December 4, 2003
Retrotranslocation of MHC class I heavy chain from the endoplasmic reticulum to the cytosol is dependent on ATP supply to the ER lumen
Jörn Albring, Jens-Oliver Koopmann, Günter J Hämmerling, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2017
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon, Stefanie Mullins, Amanda Watkins, et al.
Molecular Cancer Therapeutics
|
July 5, 2021
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
James Harper, Shannon Burke, Jon Travers, et al.
Molecular Cancer Therapeutics
|
March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Shenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
Cancer Immunology Research
|
December 8, 2016
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I S Mosely, John E Prime, Richard C A Sainson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Rapid Communications in Mass Spectrometry : RCM
|
February 19, 2003
High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays
Jens-Oliver Koopmann, Jonathan Blackburn
Molecular Immunology
|
December 4, 2003
Retrotranslocation of MHC class I heavy chain from the endoplasmic reticulum to the cytosol is dependent on ATP supply to the ER lumen
Jörn Albring, Jens-Oliver Koopmann, Günter J Hämmerling, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2017
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon, Stefanie Mullins, Amanda Watkins, et al.
Molecular Cancer Therapeutics
|
July 5, 2021
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
James Harper, Shannon Burke, Jon Travers, et al.
Molecular Cancer Therapeutics
|
March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Shenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
Cancer Immunology Research
|
December 8, 2016
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I S Mosely, John E Prime, Richard C A Sainson, et al.
Page
of 1